Skip to Content

Ahmed Kaseb

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Research Interests

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard, Unit 426
Unit Number: 426
Houston, TX 77030
Room Number: FC10.3064
Phone: 713-792-2828
Fax: 713-563-0541

Education & Training

Degree-Granting Education

1996 Cairo University School of Medicine, Cairo, Egypt, MBBS, Medicine

Postgraduate Training

7/2005-6/2007 Medical Oncology Fellow, Internal Medicine, Henry Ford Hospital, Detroit, MI
7/2004-6/2005 Internal Medicine Staff Physician, Internal Medicine, Henry Ford Hospital, Detroit, MI
7/2001-6/2004 Internal Medicine Residency, Internal Medicine, Wayne State University/Detroit Medical Center, Sanai-Grace Hospital, Detroit, MI
9/1999-6/2001 Research Fellowship, Pediatrics and Human Genetics, University of Michigan, Ann Arbor, MI
12/1998-6/1999 Externship, Internal Medicine, Michigan State University, East Lansing, MI
3/1997-2/1998 Clinical Internship, Medicine, Cairo University Hospitals, Cairo, Egypt

Board Certifications

11/2007 American Board of Medical Oncology
8/2004 American Board of Internal Medicine

Honors and Awards

2006 ASCO Foundation Merit Award, American Society of Clinical Oncology
2006 Basic Research Presentation Merit Award, 13th Annual Research Forum of Henry Ford Health System
2005 ACP Merit Award, American College of Physicians
2004 ACP Merit Award, American College of Physicians
2004 Best Ambulatory Resident Award, Sinai-Grace Hospital/Wayne State University
1990 The Egyptian Government Award, Egypt

Professional Memberships

Nexavar Advisory Board
Member, 2008-present
SWOG (Southwest Oncology Group)
Member, present

Selected Publications

Peer-Reviewed Original Research Articles
1. Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO, Curley SA, Abdalla EK, Vauthey JN. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 145(4):399-405, 4/2009. PMID: 19303988.
2. Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, Glover KY, Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol 50(2):334-41, 2/2009. e-Pub 10/2008. PMCID: PMC2658718.
3. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27(6). e-Pub 1/2009. PMID: 19139433.
4. Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, Kaseb A, Curley SA, Vauthey JN, Ellis LM, Abdalla E, Lozano RD, Patt YZ, Brown TD, Abbruzzese JL, Li D. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer 123(8):1883-91, 10/2008. PMCID: PMC2673571.
5. Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP, Reddy GP. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res 67(16):7782-8, 8/2007. PMID: 17699783.
6. Bai VU, Kaseb A, Tejwani S, Divine GW, Barrack ER, Menon M, Pardee AB, Reddy GP. Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proc Natl Acad Sci U S A 104(7):2343-8, 2/2007. e-Pub 2/2007. PMCID: PMC1892964.
7. Yang H, Yang K, Khafagi A, Tang Y, Carey TE, Opipari AW, Lieberman R, Oeth PA, Lancaster W, Klinger HP, Kaseb AO, Metwally A, Khaled H, Kurnit DM. Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A 102(21):7683-8, 5/2005. PMCID: PMC1140403.

Abstracts
1. Kaseb A, Iwasaki I, Javle M, Onicescu G, Garrett-Mayer E, Abbruzzese JL, Thomas MB. Biological Activity of Bevacizumab and Erlotinib in Patients with Advanced Hepatocellular Carcinoma (HCC). J Clin Oncol 27(15s):suppl (#4522), 2009.
2. Hammand N, Philip PA, Shields AF, Sarkar FH, Abbruzzese JL, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, El-Rayes BF. A Phase II Study of Isoflavone, Gemacitabine, and Erlotinib in Locally Advanced (LA) or Metastatic Pancreatic Cancer. J Clin Oncol 26(May 20 suppl; abstr 15540) (#15540), 2008.
3. Kaseb AO, Banerjee S, Wang Z, Sarkar FH, Ramzi M. Enhanced chemosensitivity to gemcitabine and oxaliplatin by thymoquinone in pancreatic cancer. J Clin Oncol 26(May 20 suppl; abstr 15565) (#15565), 2008.
4. Kaseb AO,Bansal M, Wollner I, Shah V, Moonka D, Divine G, Abouljoud M. A 10-year retrospective analysis of risk factors, patterns of cancer recurrence, and survival after liver transplant for cirrhosis and hepatocellular carcinoma. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I Vol 25(No. 18S(June 20 suppl)) (#4617), 2007.
5. Kaseb A, Tejwani S, Chinnakannu K, Barrack E, Reddy P. Thymoquinone, a component of the herb Nigella sativa, suppresses proliferation and viability of prostate cancer cells by down-regulating androgen receptor and E2F-1. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I Vol 24(No. 18S (June 20 suppl)) (#20038), 2006.
6. Kaseb AO, Kurnit DM. Human Papilloma Virus (HPV-16) as a Surrogate Marker for Schistosomiasis-Induced Bladder Cancer. J Clin Oncol 2005 ASCO Annual Meeting Proceedings, Vol 23, No. 16S(Part I of II (June 1 suppl)) (#4687), 2005.

Book Chapters
1. Hassan M, Kaseb A. Epidemiology and Pathogenesis of Hepatocellular Carcinoma. In: Hepatocellular Carcinoma: A Multidisciplinary Approach. Ed(s) McMasters K, Vauthey JN. Humana Press. In Press.
2. Kaseb A, Selim Abdel-Hafez. Molecular Targets and Therapeutic Uses of Kalonji (Thymoquinone). In: Molecular Targets and Therapeutic Uses of Spices: Modern Uses for Ancient Medicine. World Scientific Publishing Co., Inc. In Press.
3. Kaseb A, Thomas M. Ther Future: Combination Systemic Therapy for Hepatocellular Carcinoma. In: Hepatocellular Carcinoma: A Multidisciplinary Approach. Ed(s) McMasters K, Vauthey JN. Humana Press. In Press.
4. Kaseb A, Thomas M, Curley S. Gall Bladder and Bile Duct Cancer. In: Cancer Medicine, 8.
5. Kaseb A, Thomas M. Chemotherapy and Novel Therapies. In: Hepatocellular Carcinoma: A Practical Approach. Ed(s) Bolini L, Reddy K, Al Knawy B. Informa Health Care Publishing Co., Inc. United Kingdom, 2008.
6. Azmi AS, Mohammad M, Kaseb A, Sarkar F, Mohammad RM. Utility of Animal Models in Pancreatic Cancer Research. In: Pancreatic Cancer. Chapter 34. Springer: New York, NY, 577-599, 2008.
7. Kaseb A, Tejwani S. Biological Response Modifiers in Cancer Therapy. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Ed(s) Kohli K. Elsevier, 2006.
8. Kaseb A, Tejwani S. Cancer Gene Therapy. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Ed(s) Kohli K. Elsevier, 2006.
9. Kaseb A, Tejwani S. Vaccines in Medical Oncology. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Ed(s) Kohli K. Elsevier Publishing Co., Inc., 2006.

Last updated: 9/15/2009